Skip to content Skip to sidebar Skip to footer
Disease of the Month: Epilepsy
Disease of the Month: Epilepsy
INTRODUCTIONAlso known as seizure disorder, epilepsy is a non-communicable chronic disorder of the brain and is the fourth most common neurological disease globally. It is a central nervous system (CNS) disorder characterized by recurrent episodes of seizures that are short changes in normal brain activity which led to brief incidences of involuntary movements either…
Viewpoints_Dr. Susana Banerjee
Dr. Susana Banerjee, Medical Oncologist at The Royal Marsden Shares Insights from the SOLO-1 P-III Trial of Lynparza in Patients with BRCA Mutated Ovarian Cancer
Shots:Dr. Susan talked about the results from the SOLO-1 P-III trial of Lynparza in patients with BRCA mutated (BRCAm) newly diagnosed advanced ovarian cancer presented at ESMO’22Dr. Susan also spoke about the overall survival of this 7-year follow-up study.The 7-year follow-up of SOLO-1 showed that olaparib provided a clinically meaningful improvement in OS…
Prescription Drugs Top 20 2021
Top 20 Prescription Drugs Based on 2021 Total Revenue
Shots:The pharmaceutical companies have shown continual efforts towards developing enhanced and innovative treatment options to address the unmet needs of patients with disease eradication being the goal of developing these treatmentsAdvancements in cellular and molecular biology have increased the possibilities for generating new pharmaceutical products imposing major impacts on the prevention, diagnosis, and…
Viewpoints_Dr. Bill La Via
Dr. Bill La Via, Medical Director at Sanofi Shares Insights from the Findings that Support the Need of Protecting Infants from Respiratory Syncytial Virus (RSV)
Shots:Bill spoke about Respiratory Syncytial Virus and how it can severely affect infants' healthBill also talked about the 14 studies on RSV published in the Journal of Infectious Diseases (JID)The interview gives an understanding of how Sanofi’s vision to develop innovative solutions to help reduce the burden of RSV on infants, families,…
Viewpoints_Simon Portsmouth
Simon Portsmouth, VP, Head of Clinical Development, Shionogi Shares Insights from the New Data on an Antibiotic to Treat Bacterial Infections
Shots:Simon spoke about the new data on FETROJA (cefiderocol), an antibiotic for the treatment of serious Gram-negative (highly resistant) bacterial infectionsHe also talked about Shionogi’s agreement with GARDP & CHAI for the manufacturing and commercialization of cefiderocol in different countriesThe interview summarizes how Shionogi is advancing by developing medicines to treat serious…
Viewpoints_Martin Kilsgård
Martin Kilsgård, Head of Product at Trialbee, Shares Insights from the Launch of Trialbee Honey™ Analytics at DPHARM 2022
Shots:Martin gave a detailed view of the newly launched Honey Analytics module associated with the Trialbee Honey™ platformHe also talked about the how Trialbee Honey platform will help in the screening and recruiting of patients specifically in remote areasThe interview gives a profound understanding of how Trialbee is developing real-time monitoring modules…

Sign Up to Our Newsletter

Be the first to know the latest updates

[mc4wp_form id="13387" element_id="style-1"]